Pallas Health vs TMates: which online GLP-1 option fits you
Pallas Health vs TMates: quick verdict
Pallas Health and TMates both offer clinician-supervised compounded GLP-1 care, but they differ on pricing structure, medication choice, and provider access. Early verdict: choose Pallas Health if you want the option of FDA-approved brand-name pens or per-patient compounded tirzepatide and semaglutide with a low introductory month; choose TMates if you prefer a flat $199/month semaglutide plan with 24/7 U.S. doctor access and consistent pricing at every dose.
How they differ at a glance
This comparison focuses on the most distinctive, supported differences between Pallas Health and TMates: pricing model and cadence, medication options, clinician access and state coverage, compounding and regulatory notes, and shipping and plan inclusions. The primary keyword Pallas Health vs TMates appears here and guides the comparison.
| Criteria | Pallas Health | TMates |
|---|---|---|
| Starting price | Compounded semaglutide $139 first month | $199/month flat |
| Ongoing pricing cadence | Compounded semaglutide then $597 every 12 weeks (a $199/mo average) | Flat $199/month at every dose, no step-up fees |
| Medication choices | FDA-approved Wegovy, Ozempic, Zepbound, Mounjaro plus compounded semaglutide and tirzepatide | Compounded semaglutide only in publicly available details |
| Clinician access and coverage | 100% online; asynchronous in most states (43 of 50 need no video visit); clinician review required | 24/7 U.S. doctor access and licensed coverage in all 50 states |
| Shipping and plan inclusions | Free expedited, discreet shipping; provider care, check-ins and messaging included; no membership fee | Free shipping; virtual check-ins and 24/7 doctor access; cancel anytime |
Pricing structure and billing cadence
Pallas Health uses a mixed pricing approach. For compounded semaglutide Pallas lists a first month from $139, then $597 every 12 weeks which the provider presents as a $199/month average. Pallas also lists compounded tirzepatide at $179 first month then $897 every 12 weeks (a $299/mo average). TMates presents a flat $199/month rate at every dose with no step-up fees as dose escalates. If budgeting predictable monthly cost is most important, TMates’ flat $199/month is explicit. If a low introductory month or access to branded pens matters, Pallas Health documents a first-month pricing option starting at $139.
See TMates pricing and plan details
Medication availability and formulation
Pallas Health documents both FDA-approved brand pens including Wegovy, Ozempic, Zepbound and Mounjaro and clinician-personalized compounded semaglutide and tirzepatide prepared in the USA when a brand medication is not the right fit. TMates’ public detail emphasizes clinically dosed compounded semaglutide formulated in U.S. facilities and gives limited public detail on tirzepatide availability. That means Pallas explicitly offers brand-name options in addition to compounded choices while TMates focuses on compounded semaglutide in its marketing material.
Clinician access, state coverage and care model
Pallas Health is 100% online and says care is asynchronous in most states, noting that 43 of 50 states need no video visit while a video visit is required in seven states plus Washington, D.C. TMates states licensed coverage in all 50 states and advertises 24/7 access to U.S.-based doctors rather than messaging-only support. If continuous physician availability across all states is a priority, TMates documents 24/7 U.S. doctor access and national coverage. If you prefer a single intake that can route to either a brand pen or a compounded product and can tolerate asynchronous care in many states, Pallas documents that model.
Check Pallas Health clinician and medication options
Compounding, regulatory notes and plan inclusions
Both providers make clear that their compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas specifies that compounded medications are prepared by US-licensed compounding pharmacies and that Pallas does not manufacture or compound medication. Pallas also highlights that plan prices include provider care, ongoing check-ins and care-team messaging with no membership fee and that compounded plans are priced by medication rather than by milligram so titration does not raise the plan price. TMates highlights medications formulated in U.S.-based facilities, clinician dosing, and virtual check-ins with 24/7 physician availability.
Shipping, cancellation and logistics
Pallas advertises free expedited discreet shipping on every plan and notes that compounded plans renew every 12 weeks which affects cancellation timing. TMates advertises free shipping and cancel anytime. Availability for both is subject to medical eligibility and a U.S.-licensed clinician’s review.
Compare TMates clinical access and shipping
Final take: Pallas Health vs TMates
Both Pallas Health and TMates offer clinician-supervised, U.S.-formulated compounded GLP-1 care, but they emphasize different priorities. Pallas Health emphasizes choice between FDA-approved brand pens and compounded options, a low first-month price on compounded plans starting at $139, and plan pricing that is by medication with 12-week renewals. TMates emphasizes a simple flat $199/month pricing at every dose, 24/7 U.S. doctor access, and licensed coverage in all 50 states. The right pick depends on whether you value medication choice and an introductory price or prefer flat predictable monthly billing and round-the-clock physician access.
Choose Pallas Health if you want brand-name pens as an option, compounded semaglutide or tirzepatide with a first month from $139, and a plan price that includes clinician care and messaging.
Choose TMates if you want a flat $199/month semaglutide program with no step-up fees, 24/7 U.S. doctor access, and licensed coverage in all 50 states.